Pharmacological Treatment of Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a relatively rare disease; consequently, many patients remain unfamiliar with it in today’s society. What are the pharmacological treatment options for ankylosing spondylitis?
Pharmacological Treatment Options for Ankylosing Spondylitis
Medications used in the management of ankylosing spondylitis include the following:
- Biologic agents: Currently among the most effective treatments for AS. Tumor necrosis factor (TNF) inhibitors—such as etanercept and infliximab—are the most commonly prescribed. Prior to initiating therapy, patients must undergo appropriate screening. Those with active tuberculosis, hepatitis, malignancy, or other active infections should only use these agents under strict physician supervision.
- Nonsteroidal anti-inflammatory drugs (NSAIDs): First-line therapy for patients without contraindications—for example, meloxicam, diclofenac, and celecoxib. These agents provide anti-inflammatory and analgesic effects, alleviating symptoms. They may also be used long-term once disease activity has stabilized.
- Slow-acting antirheumatic drugs (SAARDs): Commonly used agents include sulfasalazine and thalidomide. Their therapeutic effects develop gradually and require prolonged administration.

The primary clinical manifestations of ankylosing spondylitis include: initial onset of low back pain or lumbar spine pain accompanied by morning stiffness. Patients may also experience dull pain in one or both buttocks or the inguinal region. Symptoms typically worsen with rest or prolonged sitting—especially at night.

Classic features include inflammatory low back pain and enthesitis—e.g., pain at entheseal sites such as the heels or plantar fascia insertion points—as well as pain involving the knees, costosternal joints, or spinous processes. We hope this information proves helpful to you.